Skip to main content
OpenTrials
Completed

NCT Number: NCT00483704

Multiple Attacks Study to Compare the Efficacy and Safety of MK-0974 With Placebo for Acute Migraine (MK-0974-031)

The purpose of the study is to assess the safety and efficacy of telcagepant (MK-0974) in acute treatment of multiple migraine attacks with or without aura. Primary hypotheses of this study are that telcagepant is superior to placebo, as measured by the proportion of participants who have pain freedom, pain relief, pain freedom consistency, pain relief consistency, and absence of photophobia, phonophobia, and nausea at 2 hours post-dose.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Migraines Brain Diseases Central Nervous System Diseases Headache Disorders Headache Disorders, Primary Migraine Disorders Nervous System Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • History of migraines within the past year
  • 1 to 8 moderate or severe migraine attacks per month in the past 2 months that lasted between 4 to 72 hours if untreated
  • Use acceptable contraception throughout the study
  • Able to complete the study questionnaire(s) and paper diary
  • Limit consumption of grapefruit juice to no more than one 8 ounce glass a day

Exclusion criteria

  • Pregnant or breast-feeding or is expecting to become pregnant during the study
  • Difficulty distinguishing his/her migraine attacks from tension or interval headaches
  • A history of mostly mild migraine attacks or migraines that usually resolve spontaneously in less than 2 hours
  • More than 15 headache-days per month or has taken medication for acute headache on more than 10 days a month in the past 3 months
  • Greater than 50 years old at the age of migraine onset
  • Previously taken telcagepant

Treatment and study plan

Telcagepant 140 mg

Drug

Telcagepant 140 mg tablets

Talcagepant 280 mg

Drug

Telcagepant 280 mg tablets

Placebo

Drug

Placebo tablets

Primary outcomes

  1. Percentage of Participants Reporting Pain Freedom at 2 Hours Post-dose (First Migraine Attack)

    Time frame: 2 hours post-dose for the first migraine attack (up to 6 months)

    Pain Freedom (PF) at 2 hours post-dose (first migraine attack), with pain freedom defined as a reduction in headache severity from Grade 3/2 at baseline to Grade 0 at 2 hours post-dose. Headache severity was subjectively rated by the participant at predefined time points on a scale of Grade 0 to Grade 3: Grade 0 - No pain; Grade 1 - Mild pain; Grade 2 - Moderate Pain; and Grade 3 - Severe Pain.

  2. Percentage of Participants Reporting Pain Relief at 2 Hours Post-dose (First Migraine Attack)

    Time frame: 2 hours post-dose for the first migraine attack (up to 6 months)

    Pain Relief (PR) at 2 hours post-dose (first migraine attack), with pain relief defined as a reduction in headache severity from Grade 3/2 at baseline to Grade 1/0 at 2 hours post-dose. Headache severity was subjectively rated by the participant at predefined time points on a scale of Grade 0 to Grade 3: Grade 0 - No pain; Grade 1 - Mild pain; Grade 2 - Moderate Pain; and Grade 3 - Severe Pain.

  3. Percentage of Participants Reporting Pain Freedom Consistency at 2 Hours Post-dose

    Time frame: 2 hours post-dose (up to 6 months)

    Pain Freedom Consistency (PFC) at 2 hours post-dose, defined as having achieved PF at 2 hours post-dose on at least 3 treated migraine attacks. Note that for the control groups, a positive PF response arising from the administration of the 1 talcagepant treated migraine attack will count as one of the 3 positive PF responses needed to fulfill the criteria for PFC.

  4. Percentage of Participants Reporting Pain Relief Consistency at 2 Hours Post-dose

    Time frame: 2 hours post-dose (up to 6 months)

    Pain Relief Consistency (PRC) at 2 hours post-dose, defined as having achieved PR at 2 hours post-dose on at least 3 treated migraine attacks. Note that for the control groups, a positive PR response arising from the administration of the 1 telcagepant treated migraine attack will count as one of the 3 positive PR responses needed to fulfill the criteria for PRC.

  5. Percentage of Participants Reporting Absence of Photophobia at 2 Hours Post-dose (First Migraine Attack)

    Time frame: 2 hours post-dose for the first migraine attack (up to 6 months)

    The participant recorded whether photophobia (sensitivity to light) was present or absent at each of the predefined time points.

  6. Percentage of Participants Reporting Absence of Phonophobia at 2 Hours Post-dose (First Migraine Attack)

    Time frame: 2 hours post-dose for the first migraine attack (up to 6 months)

    The participant recorded whether phonophobia (sensitivity to sound) was present or absent at each of the predefined time points.

  7. Percentage of Participants Reporting Absence of Nausea 2 Hours Post-dose (First Migraine Attack)

    Time frame: 2 hours post-dose for the first migraine attack (up to 6 months)

    The participant recorded whether nausea was present or absent at each of the predefined time points.

  8. Number of Participants Experiencing an Adverse Event (AE) Within 48 Hours Post-dose (First Migraine Attack)

    Time frame: Up to 48 hours post-dose for the first migraine attack (up to 6 months)

    AEs were reported following treatment for the first migraine attack using a 48-hour post-dose window. AEs displayed are those reported by at least 4 participants in one or more treatment groups.

  9. Number of Participants Discontinuing Study Medication Due to an AE

    Time frame: Up to the 4th dose of study medication (up to 6 months)

    Participants discontinuing study medication due to an AE were reported for all migraine attacks.

Secondary outcomes

  1. Percentage of Participants Reporting Sustained Pain Freedom From 2 to 24 Hours Post-dose (First Migraine Attack)

    Time frame: From 2 to 24 hours post-dose for the first migraine attack (up to 6 months)

    Sustained Pain Freedom (SPF) from 2 to 24 hours after study medication administration. SPF from 2 to 24 hours post-dose is defined as PF at 2 hours, with no administration of either rescue medication or the optional second dose and with no occurrence thereafter of a mild/moderate/severe headache during the 2 to 24 hours after dosing with the study medication.

  2. Percentage of Participants Reporting Sustained Pain Freedom From 2 to 48 Hours Post-dose (First Migraine Attack)

    Time frame: From 2 to 48 hours post-dose for the first migraine attack (up to 6 months)

    Sustained Pain Freedom (SPF) from 2 to 48 hours post-dose after study medication administration. SPF from 2 to 48 hours post-dose is defined as PF at 2 hours, with no administration of either rescue medication or the optional second dose and with no occurrence thereafter of a mild/moderate/severe headache during the 2 to 48 hours after dosing with the study medication.

  3. Percentage of Participants Reporting Total Migraine Freedom at 2 Hours Post-dose (First Migraine Attack)

    Time frame: 2 hours post-dose for the first migraine attack (up to 6 months)

    TMF 2 hours post-dose, which is defined as TMF at 2 hours post-dose, with no administration of either rescue medication or the optional second dose and with no occurrence thereafter of a mild/moderate/severe headache and no reported occurrence of photophobia, phonophobia, nausea, or vomiting during the 2 hours after dosing with the study medication.

  4. Percentage of Participants Reporting Total Migraine Freedom From 2 to 24 Hours Post-dose (First Migraine Attack)

    Time frame: From 2 to 24 hours post-dose for the first migraine attack (up to 6 months)

    TMF from 2 to 24 hours post-dose, which is defined as TMF at 2 hours post-dose, with no administration of either rescue medication or the optional second dose and with no occurrence thereafter of a mild/moderate/severe headache and no reported occurrence of photophobia, phonophobia, nausea, or vomiting during the 2 to 24 hours after dosing with the study medication.

Sponsors and collaborators

Lead sponsor

Merck Sharp & Dohme LLC

Industry

Registry information

Official study title

A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Multiple Attacks Study to Compare the Efficacy and Safety of Oral MK-0974 With Placebo for the Acute Treatment of Migraine With or Without Aura

Important dates

Study start
2008
Primary completion
2009
Study completion
2009
First posted
Jun 7, 2007
Registry last updated
Oct 18, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.